IBT High Throughput Research and Screening Center

Overview of Services

While there have been spectacular advances in our ability to understand the basic mechanisms that contribute
to the growth of many types of disease, there remain significant challenges in translating these discoveries into treatments that are of direct benefit to patients. Part of the problem is that many researchers lack access to the types of specialized resources for drug discovery that are available to scientists working in pharmaceutical companies. The goal of the IBT High Throughput Screening Program, has been to provide researchers with access to state-of-the-art facilities and cutting-edge technologies that they can use to translate the results of their research into new treatments for disease. The Combinatorial Drug Discovery Program (CDDP) is a critical component of this larger program. The CDDP is focused on helping researchers to repurpose existing approved drugs, either alone or more often in combination, to treat different types of disease. The great advantage of drug repurposing is that a great deal is already known about the properties of established drugs, their side effects, their dosing requirements etc. making it much cheaper and much faster to get them into the clinic than if they were brand new drugs. Research supported by this core facility will have a direct impact on the development of new treatments for many diseases.


Peter Davies

Clifford Stephan
Scientific Director

Location and hours of operation

Hours Location

Staffed 8am - 6pm M-Sa        

2121 W. Holcombe Blvd
Institute of Biosciences and Technology
Texas A&M College of Medicine Houston, TX 77030

Links and Resources

  1. IBT Cores listing
  2. Stephan Lab/Screening Core specific
  3. TxSACT Homepage


Name Role Phone Email Location
Clifford Stephan
Scientific Director
Houston, Texas
Nghi Nguyen
Research Specialist
Houston, Texas
Denelle Orellana
Sr. Administrative Coordinator I
Houston, Texas